Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Deffered Revenue (2016 - 2018)

Ironwood Pharmaceuticals' Non-Current Deffered Revenue history spans 9 years, with the latest figure at $6.3 million for Q4 2018.

  • On a quarterly basis, Non-Current Deffered Revenue rose 15.76% to $6.3 million in Q4 2018 year-over-year; TTM through Dec 2018 was $6.3 million, a 15.76% increase, with the full-year FY2018 number at $6.3 million, up 15.76% from a year prior.
  • Non-Current Deffered Revenue hit $6.3 million in Q4 2018 for Ironwood Pharmaceuticals, up from $6.1 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for IRWD hit a ceiling of $10.5 million in Q4 2014 and a floor of $557000.0 in Q4 2016.
  • Historically, Non-Current Deffered Revenue has averaged $6.1 million across 5 years, with a median of $6.1 million in 2018.
  • Biggest five-year swings in Non-Current Deffered Revenue: tumbled 91.29% in 2016 and later soared 878.28% in 2017.
  • Tracing IRWD's Non-Current Deffered Revenue over 5 years: stood at $10.5 million in 2014, then tumbled by 39.22% to $6.4 million in 2015, then tumbled by 91.29% to $557000.0 in 2016, then soared by 878.28% to $5.4 million in 2017, then grew by 15.76% to $6.3 million in 2018.
  • Business Quant data shows Non-Current Deffered Revenue for IRWD at $6.3 million in Q4 2018, $6.1 million in Q3 2018, and $6.1 million in Q2 2018.